| Income Statement | 2025-08-31 | 2025-05-31 | 2024-08-31 | |
|---|---|---|---|---|
| Revenue | 7,825,432 | 7,928,843 | 8,066,715 | |
| Change in fair value of contingent consideration | - | - | 12,702 | |
| Cost of sales | 1,801,419 | 1,856,539 | 2,125,846 | |
| Selling, general and administrative expenses | 3,876,159 | 4,257,857 | 4,149,785 | |
| Impairment of investment-Tianhe Stem Cell Biotechnologies Inc | 0 | 0 | - | |
| Research, development and related engineering | 61,625 | 131,711 | 193,933 | |
| Depreciation and amortization | 185,693 | 190,102 | 194,559 | |
| Total costs and expenses | 5,924,896 | 6,436,209 | 6,676,825 | |
| Operating income | 1,900,536 | 1,492,634 | 1,389,890 | |
| (losses) gains on marketable securities | -193,886 | -379,332 | 522,458 | |
| Gain on interest rate swap | 0 | 0 | - | |
| Other income | 17,565 | 12,927 | 981 | |
| Interest expense | 538,219 | 551,126 | 533,464 | |
| Total other income (expense) | -714,540 | -917,531 | -10,025 | |
| Income before income tax expense | 1,185,996 | 575,103 | 1,379,865 | |
| Income tax expense | 436,588 | 219,318 | 328,186 | |
| Net income | 749,408 | 355,785 | 1,051,679 | |
| Earnings per share, basic | 0.09 | 0.04 | 0.13 | |
| Earnings per share, diluted | 0.09 | 0.04 | 0.13 | |
| Weighted average number of shares outstanding, basic | 8,057,780 | 8,080,161 | 8,061,946 | |
| Weighted average number of shares outstanding, diluted | 8,073,654 | 8,125,720 | 8,173,535 | |
CRYO CELL INTERNATIONAL INC (CCEL)
CRYO CELL INTERNATIONAL INC (CCEL)